An autopsy case of EBV-positive CD8+ T cell lymphoma after allogeneic transplantation of peripheral blood stem cells
Main Article Content
Abstract
An autopsy case of CD8+ T cell lymphoma after allogenic transplantation of peripheral blood stem cells (PBSC) is presented. A 57-year-old man was first diagnosed with diffuse large B cell lymphoma (DLBCL) based on a biopsy of an inguinal lymph node. The disease progressed with poor response to chemotherapy, and pathological diagnosis was reviewed. The revised diagnosis was angioimmunoblastic T-cell lymphoma (AITL) with secondary development of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL). The patient died 114 days post-allogenic hematopoietic stem cell transplantation (allo-HSCT) and an autopsy was performed. EBV-positive CD8+ cells were systematically observed in organs, including the liver, spleen, gastrointestinal tracts, and lungs. Liver injury was also apparent with sinusoidal obstruction syndrome (SOS) / veno-occlusive disease (VOD), causing splenomegaly. Southern blot analysis of peripheral blood cells revealed the presence of monoclonal EBV DNA, indicating monoclonal expansion of EBV-positive CD8+ cells.
The present case uniquely displayed EBV-positive T-cell post-transplant lymphoproliferative disorder (PTLD), with monoclonal expansion of CD8+ cells. Although its pathophysiology is not fully understood, this is a typical and precious case of posttransplant EBV-positive T-cell lymphoma, designated in the upcoming WHO classification of haematolymphoid tumours, 5th edition.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Jiang C, Huang J, Shao J, et al. T-Cell Posttransplant Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation: Case Series and Systemic Review. Cell Transplant. Jan-Dec 2024;33:9636897241259722. doi:10.1177/09636897241259722
3. Kuno M, Ito A, Maeshima AM, et al. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Int J Hematol. Aug 2020;112(2):193-199. doi:10.1007/s12185-020-02890-1
4. Tiede C, Maecker-Kolhoff B, Klein C, Kreipe H, Hussein K. Risk factors and prognosis in T-cell posttransplantation lymphoproliferative diseases: reevaluation of 163 cases. Transplantation. Feb 15 2013;95(3):479-88. doi:10.1097/TP.0b013e3182762e07
5. Quintanilla-Martinez L, Swerdlow SH, Tousseyn T, Barrionuevo C, Nakamura S, Jaffe ES. New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. Virchows Arch. Jan 2023;482(1):227-244. doi:10.1007/s00428-022-03414-4
6. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. Jul 2022;36(7):1720-1748. doi:10.1038/s41375-022-01620-2
7. Morscio J, Tousseyn T. Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders. World J Transplant. Sep 24 2016;6(3):505-16. doi:10.5500/wjt.v6.i3.505
8. Styczynski J, van der Velden W, Fox CP, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. Jul 2016;101(7):803-11. doi:10.3324/haematol.2016.144428
9. Dojcinov SD, Quintanilla-Martinez L. How I Diagnose EBV-Positive B- and T-Cell Lymphoproliferative Disorders. Am J Clin Pathol. Jan 4 2023;159(1):14-33. doi:10.1093/ajcp/aqac105
10. Sugimoto A, Watanabe T, Matsuoka K, et al. Growth Transformation of B Cells by Epstein-Barr Virus Requires IMPDH2 Induction and Nucleolar Hypertrophy. Microbiol Spectr. Aug 17 2023;11(4):e0044023. doi:10.1128/spectrum.00440-23
11. Margolskee E, Jobanputra V, Jain P, et al. Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders. Oncotarget. Jun 21 2016;7(25):37636-37648. doi:10.18632/oncotarget.9400
12. Coleman CB, Wohlford EM, Smith NA, et al. Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines. J Virol. Feb 2015;89(4):2301-12. doi:10.1128/JVI.03001-14
13. Smith NA, Coleman CB, Gewurz BE, Rochford R. CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells. J Virol. May 18 2020;94(11)doi:10.1128/JVI.00428-20
14. Dayton JS, Lindsten T, Thompson CB, Mitchell BS. Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression. J Immunol. Feb 1 1994;152(3):984-91.
15. Clerico M, Dogliotti I, Aroldi A, et al. Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options. J Clin Med. Dec 19 2022;11(24)doi:10.3390/jcm11247542